$HWBK

Hawthorn Bancshares (NASDAQ:HWBK) Rating Increased to Buy at Wall Street Zen

Hawthorn Bancshares (NASDAQ:HWBK) had its rating upgraded from "hold" to "buy" by Wall Street Zen, while Weiss Ratings reissued a "hold (c)" rating. The stock opened down approximately 2.9% at $33.88. Several institutional investors have recently increased or initiated positions in the company, with institutions now owning about 30.73% of the stock.

Original reporting
MarketBeat · MarketBeat
Published Dec 13, 2025, 7:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Dec 13, 2025, 8:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hawthorn Bancshares (NASDAQ:HWBK) Rating Increased to Buy at Wall Street Zen — source image
Decision brief

The 30-second read

$HWBKNeutralMed
01

Why it matters

The upgrade and institutional activity could lead to short-term price appreciation, but the immediate downtrend warrants caution.

02

Market read

The news has moderate relevance for short-term traders focusing on regional banks, with limited impact on broader markets.

03

What to watch

Potential upcoming earnings reports or macroeconomic events could influence stock performance independently of the recent rating change.

Relevance 6/10Timing: short-term (1-3 weeks)

Background

Hawthorn Bancshares received a rating upgrade from 'hold' to 'buy' by Wall Street Zen amid increased institutional interest, indicating a potential shift in market perception.

Company-level read

Ticker impact

$HWBKNeutralMedium confidence
Context

The news pertains directly to Hawthorn Bancshares, a regional bank, with recent rating upgrades and institutional interest, indicating potential short-term trading opportunities.

Expected impact

Moderate upward price movement expected over the next 1-3 weeks, contingent on broader market conditions.

Evidence & confidence

The upgrade and institutional interest are positive signals, but the immediate decline in share price and mixed ratings warrant cautious optimism.

Market effects

Potential positive sentiment for regional banks, possibly influencing sector ETFs.

Limited to the regional banking sector; broader market impact minimal.

Negligible.

Counterpoint

The initial decline suggests market skepticism; the rating upgrade may be a reaction to short-term factors rather than fundamental strength.

Key entities

  • Wall Street Zen

    The entity that upgraded the stock to 'buy'.

  • Weiss Ratings

    Reissued a 'hold' rating, indicating mixed analyst sentiment.

Related articles

$HWBKMed

HAWTHORN BANCSHARES, INC. (HWBK): Completion of Acquisition or Disposition of Assets

HAWTHORN BANCSHARES, INC. (HWBK) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 PRESS RELEASE – FOR IMMEDIATE RELEASE Hawthorn Bancshares, Inc. Completes Merger with FSC Bancshares, Inc. JEFFERSON CITY, Mo., Sept. 4, 2026 /GLOBE NEWSWIRE/ -- Hawthorn Bancshares, Inc. (“Hawthorn”) (NASDAQ: HWBK), the Missouri-based holding company of Hawthorn Ban

$HWBKMed

Hawthorn Bancshares Reports Second Quarter 2026 Results

HAWTHORN BANCSHARES, INC. (HWBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hawthorn Bancshares Reports Second Quarter 2026 Results Jefferson City, MO — July 29, 2026 — Hawthorn Bancshares, Inc. (NASDAQ: HWBK) , (the “Company”), the bank holding company for Hawthorn Bank, reported second quarter 2026 net income of $7.3 million, or earnings p

$SHOPMed

Oppenheimer sees web, commerce software Q3 backdrop improving, AI worries linger

Oppenheimer notes improved interest in web and e-commerce software ahead of Q3 results, but AI concerns remain. Shopify (SHOP) is expected to exceed revenue forecasts with strong consumer demand. Wix.com (WIX) may see slower growth due to AI shifts. GoDaddy (GDDY) is on track with forecasts, and Commerce.com (CMCM) expects revenue in line with estimates. Oppenheimer raised Shopify's price target to $205.

$RAPPMedAI 9/10

Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics (NASDAQ: RAPP) announced positive Phase II trial results for RAP-219 in bipolar mania, with plans to advance to Phase III. The drug was well-tolerated, with mild to moderate adverse events. The company aims to meet with the FDA in Q1 2027 and start Phase III trials in the second half of 2027. Rapport also expects to report long-term safety data for RAP-219 in focal onset seizures in Q4 2026.